ライフサイエンスコーパス: monoclonal gammopathy

1 iocytosis is a rare disorder associated with monoclonal gammopathy.

2 or hereditary amyloidosis with a concomitant monoclonal gammopathy.

3 into bone marrow and the presence of an IgM monoclonal gammopathy.

4 inosis, extracutaneous manifestations, and a monoclonal gammopathy.

5 coni syndrome (FS) is a rare complication of monoclonal gammopathy.

6 from the sera of individuals with a form of monoclonal gammopathy.

7 a cell leukemia (PCL) is the most aggressive monoclonal gammopathy.

8 ot analysis, primarily in presence of an IgM monoclonal gammopathy.

9 utcomes of eosinophilic fasciitis-associated monoclonal gammopathy.

10 for histology in patients who do not have a monoclonal gammopathy.

11 proportion of patients will have persistent monoclonal gammopathy.

12 anscriptional reorganization of AL and other monoclonal gammopathies.

13 , University College London, and Registry of Monoclonal Gammopathies.

14 irected or B cell clone-directed therapy for monoclonal gammopathies.

15 um and glutamate than patients with indolent monoclonal gammopathies.

16 by CD138(+) cells across the progression of monoclonal gammopathies.

17 n has been implicated in the pathogenesis of monoclonal gammopathies.

18 se-associated gammopathies and some sporadic monoclonal gammopathies.

19 Gaucher's disease have an increased risk of monoclonal gammopathies.

20 irus (EBV) replication in the persistence of monoclonal gammopathy.1 It has been known for some time

21 % vs. 11%), multiple myeloma (8% vs. 0), and monoclonal gammopathy (22% vs. 16%).

22 vated erythropoietin and erythrocytosis; (3) monoclonal gammopathy; (4) perinephric fluid collections

23 Further investigation revealed a monoclonal gammopathy, a unique patterning of subcutaneo

24 se characterized by urticarial exanthema and monoclonal gammopathy accompanied by systemic symptoms s

25 yeloma (CMM) are preceded by an asymptomatic monoclonal gammopathy (AMG), classified as either monocl

26 d and 2% of symptomatic patients) had both a monoclonal gammopathy and a hereditary variant.

27 a B-cell malignancy characterized by an IgM monoclonal gammopathy and bone marrow (BM) infiltration

28 symptoms are always preceded by a detectable monoclonal gammopathy and by elevated biomarkers of orga

29 Three (21%) patients were positive for monoclonal gammopathy and had a faster rate of recurrenc

30 We review the causal association between monoclonal gammopathy and neuropathy, and critically rev

31 fection is unknown, but in many patients the monoclonal gammopathy and other B-cell abnormalities can

32 HIV infection have an increased incidence of monoclonal gammopathy and plasma cell dyscrasias.2,3 The

33 o indicate a causal relationship between the monoclonal gammopathy and the renal damage and because t

34 Hematologic workup revealed an IgG kappa monoclonal gammopathy, and bone marrow biopsy confirmed

35 me is characterized by an urticarial rash, a monoclonal gammopathy, and clinical, histological, and b

36 One patient with C3G had GN unrelated to the monoclonal gammopathy, and one with PGNMID did not compl

37 olyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome

38 olyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes) syndrome is a r

39 ber of kidney diseases associated with other monoclonal gammopathies are being recognized.

40 Monoclonal gammopathies are frequently complicated by ki

41 The IgG and IgA monoclonal gammopathies are rarely associated with speci

42 IgD monoclonal gammopathies are uncommon.

43 gnificance (MGUS) is the most commonly found monoclonal gammopathy associated with neuropathy.

44 aracterized by recurrent urticarial rash and monoclonal gammopathy, associated with clinical and biol

45 Clarkson disease [monoclonal gammopathy-associated idiopathic systemic cap

46 Clarkson disease, or monoclonal gammopathy-associated idiopathic systemic cap

47 ional immunofluorescence in the diagnosis of monoclonal gammopathy-associated kidney diseases.

48 opsy diagnosis with precision therapy in the monoclonal gammopathy-associated kidney disorders.

49 sensus-based terminology and definitions for monoclonal gammopathy-associated kidney lesions.

50 que in kidney pathology for the diagnosis of monoclonal gammopathy-associated nephropathies, and coul

51 A subgroup of patients with ISCLS have monoclonal gammopathy-associated SCLS (also known as Cla

52 f amyloid organ involvement in patients with monoclonal gammopathies at higher risk to develop the di

53 characteristics of human disease, including monoclonal gammopathy, BM infiltration with lytic bone l

54 In patients with monoclonal gammopathies, C-reactive protein may be a mor

55 pared with 2% of age-matched controls, had a monoclonal gammopathy characterized as IgG lambda in 9 p

56 ion disease (MIDD) is a rare complication of monoclonal gammopathy characterized by deposition of mon

57 Certain human sera from patients with monoclonal gammopathies contain factors that induce myel

58 Screen-detected monoclonal gammopathies correlated with increased all-ca

59 ion and test results led us to consider that monoclonal gammopathy could be the cause of this entity.

60 NA methylation in the immunoglobulin M (IgM) monoclonal gammopathy disease spectrum remains poorly un

61 In conclusion, FS associated with monoclonal gammopathy does not appear to confer an addit

62 mune cells in 305 patients with asymptomatic monoclonal gammopathy enrolled in S0120 under the auspic

63 sed on clinical and laboratory findings with monoclonal gammopathy evaluation and, if indicated, TTR

64 tologists can screen subjects who have known monoclonal gammopathy for amyloid organ dysfunction and

65 ent of peripheral neuropathy associated with monoclonal gammopathies has been advanced by recent clin

66 e spectrum of kidney lesions associated with monoclonal gammopathy has significantly expanded over th

67 ) and associated skeletal destruction, serum monoclonal gammopathy, immune suppression, and end-organ

68 Ophthalmologists should consider monoclonal gammopathies in unexplained bilateral interst

69 ocytic leukemia/small lymphocytic lymphoma), monoclonal gammopathy in 20%, and multiple myeloma in 6%

70 phritic factor in child GP patients and with monoclonal gammopathy in adult GP patients, who frequent

71 The high frequency of monoclonal gammopathy in adult patients with C3 glomerul

72 a cell dyscrasias.2,3 The exact mechanism of monoclonal gammopathy in patients with HIV infection is

73 Monoclonal gammopathy in several patients may have poten

74 trosome amplification was detected in 67% of monoclonal gammopathies, including monoclonal gammopathy

75 onal immunoglobulin in 33% of sporadic human monoclonal gammopathies is also specific for the lysolip

76 e that clinical progression in patients with monoclonal gammopathies is associated with an acquired b

77 -stage renal disease, the persistence of the monoclonal gammopathy is associated with high rates of r

78 l damage and because the significance of the monoclonal gammopathy is no longer undetermined.

79 The monoclonal gammopathy leads to abnormal deposition of li

80 2 or more years before diagnosis to detect a monoclonal gammopathy (M-Ig).

81 ion monitoring and serum electrophoresis for monoclonal gammopathy (MG or M-protein).

82 al population, the presence of non-malignant monoclonal gammopathy (MG) can be causally associated wi

83 A high prevalence of monoclonal gammopathy (MG) has been observed in HIV-infe

84 he rate and predictors of finding lesions of monoclonal gammopathy (MG) of renal significance (MGRS)

85 ic mucinosis that is usually associated with monoclonal gammopathy (MG).

86 in patients with chronic kidney disease with monoclonal gammopathy (MG).

87 Detection of light chain (LC) monoclonal gammopathies (MGs) traditionally relies on se

88 biopsy in only 15% of patients, included 21 monoclonal gammopathies of renal significance; 15 multip

89 l population can be identified as in myeloma/monoclonal gammopathies of undetermined significance (MG

90 nalysis of bone marrow trephine samples from monoclonal gammopathies of undetermined significance (MG

91 y modified paraprotein target (paratargs) in monoclonal gammopathies of undetermined significance (MG

92 from 61 patients (29 AL, 23 MM, and 9 MGUS [monoclonal gammopathies of undetermined significance]) w

93 noglobulin light-chain (AL) amyloidosis, and monoclonal gammopathy of clinical significance (MGCS), a

94 It focuses on the concept of monoclonal gammopathy of clinical significance, which ca

95 gue for CANOMAD to be included in neurologic monoclonal gammopathy of clinical significance.

96 M-protein concentrations at the monoclonal gammopathy of indeterminate potential (MGIP)

97 Given the propensity for monoclonal gammopathy of macular significance to transfo

98 noproliferative disorder that we have termed monoclonal gammopathy of macular significance.

99 tion was found in 89% of patients, including monoclonal gammopathy of renal significance (65%) and sy

100 Monoclonal gammopathy of renal significance (MGRS) defin

101 The hematologic condition was monoclonal gammopathy of renal significance (MGRS) in 55

102 Monoclonal gammopathy of renal significance (MGRS) is in

103 The term monoclonal gammopathy of renal significance (MGRS) was i

104 Recently, the term monoclonal gammopathy of renal significance (MGRS) was i

105 PGNMID) is classified within the spectrum of monoclonal gammopathy of renal significance (MGRS).

106 Hematological diagnosis was monoclonal gammopathy of renal significance in 30 (60%),

107 Hematological diagnosis was monoclonal gammopathy of renal significance in 64% and s

108 We think the term monoclonal gammopathy of renal significance is most help

109 luding multiple myeloma, AL amyloidosis, and monoclonal gammopathy of renal significance, face a high

110 underwent bone marrow biopsy which revealed Monoclonal Gammopathy of renal significance, triggering

111 tion process of normal plasma cells (PCs) to monoclonal gammopathy of uncertain significance (MGUS) a

112 tribution was determined in 63 patients with monoclonal gammopathy of uncertain significance (MGUS) a

113 hat healthy human controls and patients with monoclonal gammopathy of uncertain significance expresse

114 Aberrant demethylation in monoclonal gammopathy of uncertain significance occurred

115 from 56 subjects representing premalignant (monoclonal gammopathy of uncertain significance), early,

116 performed CGH on 25 cases of MM, 4 cases of monoclonal gammopathy of uncertain significance, and 1 c

117 as an indolent course of disease that mimics monoclonal gammopathy of undermined significance, wherea

118 ltiple myeloma (SMM) bridges the gap between monoclonal gammopathy of undetermined significance (a mo

119 34 patients with WM and 10 patients with IgM monoclonal gammopathy of undetermined significance (IgM

120 Immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (IgM-

121 amples from 58 patients with WM, 77 with IgM monoclonal gammopathy of undetermined significance (IgM-

122 Endothelial cells from patients with monoclonal gammopathy of undetermined significance (MGEC

123 er in these patients is more consistent with monoclonal gammopathy of undetermined significance (MGUS

124 Monoclonal gammopathy of undetermined significance (MGUS

125 demonstrate an increased fracture risk with monoclonal gammopathy of undetermined significance (MGUS

126 Monoclonal gammopathy of undetermined significance (MGUS

127 the original clone, referred to as secondary monoclonal gammopathy of undetermined significance (MGUS

128 le myeloma (MM) patients (n = 8740) and 5652 monoclonal gammopathy of undetermined significance (MGUS

129 The association of obesity with monoclonal gammopathy of undetermined significance (MGUS

130 istently preceded by the precursor states of monoclonal gammopathy of undetermined significance (MGUS

131 Monoclonal gammopathy of undetermined significance (MGUS

132 ich evolves from a premalignant stage called monoclonal gammopathy of undetermined significance (MGUS

133 Monoclonal gammopathy of undetermined significance (MGUS

134 Monoclonal gammopathy of undetermined significance (MGUS

135 The transformation from monoclonal gammopathy of undetermined significance (MGUS

136 Monoclonal gammopathy of undetermined significance (MGUS

137 ilial clustering of the precursor condition, monoclonal gammopathy of undetermined significance (MGUS

138 We examined whether monoclonal gammopathy of undetermined significance (MGUS

139 pesticide applicators to assess the risk of monoclonal gammopathy of undetermined significance (MGUS

140 IgM monoclonal gammopathy of undetermined significance (MGUS

141 Monoclonal gammopathy of undetermined significance (MGUS

142 Oncogenic drivers of progression of monoclonal gammopathy of undetermined significance (MGUS

143 in the etiology of multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS

144 e marrow PCs from subjects with MM (n = 16), monoclonal gammopathy of undetermined significance (MGUS

145 ve cases of multiple myeloma, three cases of monoclonal gammopathy of undetermined significance (MGUS

146 The factors that determine progression from monoclonal gammopathy of undetermined significance (MGUS

147 Monoclonal gammopathy of undetermined significance (MGUS

148 The prevalence of monoclonal gammopathy of undetermined significance (MGUS

149 21) in more than 500 untreated patients with monoclonal gammopathy of undetermined significance (MGUS

150 Monoclonal gammopathy of undetermined significance (MGUS

151 thylation is relatively common and occurs in monoclonal gammopathy of undetermined significance (MGUS

152 of bone marrow specimens from patients with monoclonal gammopathy of undetermined significance (MGUS

153 Monoclonal gammopathy of undetermined significance (MGUS

154 studies have reported a higher prevalence of monoclonal gammopathy of undetermined significance (MGUS

155 in 67% of monoclonal gammopathies, including monoclonal gammopathy of undetermined significance (MGUS

156 s of premalignant non-immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS

157 ppa or lambda immunoglobulin light chains in monoclonal gammopathy of undetermined significance (MGUS

158 rease in CD4+ CD25+ T cells in patients with monoclonal gammopathy of undetermined significance (MGUS

159 Whether this dichotomy exists in monoclonal gammopathy of undetermined significance (MGUS

160 d for multiple myeloma (MM) and premalignant monoclonal gammopathy of undetermined significance (MGUS

161 receptors on plasma cells from patients with monoclonal gammopathy of undetermined significance (MGUS

162 ed in the early pathogenesis of premalignant monoclonal gammopathy of undetermined significance (MGUS

163 The events leading the transformation of the monoclonal gammopathy of undetermined significance (MGUS

164 At diagnosis, most patients had monoclonal gammopathy of undetermined significance (MGUS

165 ression was detected in 5 of 5 patients with monoclonal gammopathy of undetermined significance (MGUS

166 been made to quantitate adverse outcomes of monoclonal gammopathy of undetermined significance (MGUS

167 A monoclonal gammopathy of undetermined significance (MGUS

168 previously untreated active myeloma, 14 had monoclonal gammopathy of undetermined significance (MGUS

169 Unlike monoclonal gammopathy of undetermined significance (MGUS

170 omal aberrations have been identified in the monoclonal gammopathy of undetermined significance (MGUS

171 ewly diagnosed multiple myeloma (MM), 5 with monoclonal gammopathy of undetermined significance (MGUS

172 arises from a common benign PC tumor called Monoclonal Gammopathy of Undetermined Significance (MGUS

173 al similarities to multiple myeloma (MM) and monoclonal gammopathy of undetermined significance (MGUS

174 V-8 may play a role in the transformation of monoclonal gammopathy of undetermined significance (MGUS

175 ifferentially expressed in plasma cells from monoclonal gammopathy of undetermined significance (MGUS

176 ic cells from two out of eight patients with monoclonal gammopathy of undetermined significance (MGUS

177 e multiple myeloma to a benign form known as monoclonal gammopathy of undetermined significance (MGUS

178 g clonal cells in the blood of patients with monoclonal gammopathy of undetermined significance (MGUS

179 Monoclonal gammopathy of undetermined significance (MGUS

180 l factors are suggested to jointly influence monoclonal gammopathy of undetermined significance (MGUS

181 uman multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined significance (MGUS

182 Hypercalcemia in monoclonal gammopathy of undetermined significance (MGUS

183 es investigate the outcomes of patients with monoclonal gammopathy of undetermined significance (MGUS

184 itions smoldering multiple myeloma (SMM) and monoclonal gammopathy of undetermined significance (MGUS

185 Monoclonal gammopathy of undetermined significance (MGUS

186 Monoclonal gammopathy of undetermined significance (MGUS

187 Monoclonal gammopathy of undetermined significance (MGUS

188 Monoclonal gammopathy of undetermined significance (MGUS

189 ently preceded by an asymptomatic condition, monoclonal gammopathy of undetermined significance (MGUS

190 ple myeloma (MM) is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS

191 recursor conditions recognized clinically as monoclonal gammopathy of undetermined significance (MGUS

192 festation of monoclonal gammopathies such as monoclonal gammopathy of undetermined significance (MGUS

193 Monoclonal gammopathy of undetermined significance (MGUS

194 Prevalence estimates for monoclonal gammopathy of undetermined significance (MGUS

195 d studies indicate a possible association of monoclonal gammopathy of undetermined significance (MGUS

196 ht-chain (AL) amyloidosis who present with a monoclonal gammopathy of undetermined significance (MGUS

197 s of multiple myeloma (MM) and its precursor monoclonal gammopathy of undetermined significance (MGUS

198 Monoclonal gammopathy of undetermined significance (MGUS

199 Multiple myeloma is consistently preceded by monoclonal gammopathy of undetermined significance (MGUS

200 (MM) are preceded by precursor states termed monoclonal gammopathy of undetermined significance (MGUS

201 sorting exosomes from multiple myeloma (MM), monoclonal gammopathy of undetermined significance (MGUS

202 Plasma cell dyscrasias, including monoclonal gammopathy of undetermined significance (MGUS

203 olves from a premalignant condition known as monoclonal gammopathy of undetermined significance (MGUS

204 peculated that the clinical progression from monoclonal gammopathy of undetermined significance (MGUS

205 M transformation from immunoglobulin-M (IgM) monoclonal gammopathy of undetermined significance (MGUS

206 of multiple myeloma and its precursor state, monoclonal gammopathy of undetermined significance (MGUS

207 n premalignant plasma cell dyscrasia such as monoclonal gammopathy of undetermined significance (MGUS

208 onsistently preceded by the precursor state, monoclonal gammopathy of undetermined significance (MGUS

209 Blood, Farr et al showed that patients with monoclonal gammopathy of undetermined significance (MGUS

210 lonal gammopathy (AMG), classified as either monoclonal gammopathy of undetermined significance (MGUS

211 ressed in bones of a subset of patients with monoclonal gammopathy of undetermined significance (MGUS

212 Monoclonal gammopathy of undetermined significance (MGUS

213 In 728 Swedish cases of monoclonal gammopathy of undetermined significance (MGUS

214 esson et al study the risk of progression of monoclonal gammopathy of undetermined significance (MGUS

215 Patients with monoclonal gammopathy of undetermined significance (MGUS

216 Monoclonal gammopathy of undetermined significance (MGUS

217 was absent in 90% of immunoglobulin M (IgM) monoclonal gammopathy of undetermined significance (MGUS

218 old woman with AL-amyloidosis secondary to a monoclonal gammopathy of undetermined significance (MGUS

219 nce interval [CI], 1.31-17.86; P = .018) and monoclonal gammopathy of undetermined significance (OR,

220 plasma cells (B cells, normal plasma cells, monoclonal gammopathy of undetermined significance [MGUS

221 with the marrow in preneoplastic gammopathy (monoclonal gammopathy of undetermined significance [MGUS

222 ldenstrom macroglobulinemia [WM], 6 with IgM monoclonal gammopathy of undetermined significance [MGUS

223 They are seen rarely as a monoclonal gammopathy of undetermined significance and a

224 ping phenotypic profiles between AL and both monoclonal gammopathy of undetermined significance and M

225 indeterminate potential (CHIP), analogous to monoclonal gammopathy of undetermined significance and m

226 rasias, including asymptomatic states called monoclonal gammopathy of undetermined significance and s

227 rates from precursor states of MM, including monoclonal gammopathy of undetermined significance and s

228 Moreover, analyses of samples from monoclonal gammopathy of undetermined significance and s

229 olution from precursor conditions, including monoclonal gammopathy of undetermined significance and s

230 Our goal was to develop a monoclonal gammopathy of undetermined significance and s

231 ias encompass a spectrum from the precursors monoclonal gammopathy of undetermined significance and s

232 attern of bone marrow involvement similar to monoclonal gammopathy of undetermined significance at di

233 Inclusion criteria were newly diagnosed MM, monoclonal gammopathy of undetermined significance at hi

234 SMM is distinguished from monoclonal gammopathy of undetermined significance by a

235 Monoclonal gammopathy of undetermined significance isoty

236 those from healthy donors and patients with monoclonal gammopathy of undetermined significance or ot

237 ded patients who were 18 years or older with monoclonal gammopathy of undetermined significance or sm

238 as asymptomatic precursor conditions-either monoclonal gammopathy of undetermined significance or sm

239 multiple myeloma are dichotomised as having monoclonal gammopathy of undetermined significance or sm

240 icroenvironment cells in transformation from monoclonal gammopathy of undetermined significance or sm

241 ecreased serum adiponectin concentrations in monoclonal gammopathy of undetermined significance patie

242 The PANGEA models improved prediction of monoclonal gammopathy of undetermined significance progr

243 Materials and Methods Patients with monoclonal gammopathy of undetermined significance prosp

244 ver different disease stages, from 23.66% in monoclonal gammopathy of undetermined significance to 3.

245 right-skewed model of genetic evolution from monoclonal gammopathy of undetermined significance to MM

246 in a pattern that parallels progression from monoclonal gammopathy of undetermined significance to MM

247 An IgG kappa monoclonal gammopathy of undetermined significance was f

248 Plasma cells in 10 patients with monoclonal gammopathy of undetermined significance were

249 n biomarkers can help identify patients with monoclonal gammopathy of undetermined significance who a

250 sionally may be the presenting feature); and monoclonal gammopathy of undetermined significance with

251 molecular characteristics that evolves from monoclonal gammopathy of undetermined significance, a hi

252 nguish POEMS from neuropathy associated with monoclonal gammopathy of undetermined significance, addi

253 h light chain amyloidosis, multiple myeloma, monoclonal gammopathy of undetermined significance, and

254 Monoclonal B-cell lymphocytosis, monoclonal gammopathy of undetermined significance, and

255 progression from the non-malignant disorder monoclonal gammopathy of undetermined significance, are

256 ight chain amyloidosis, multiple myeloma and monoclonal gammopathy of undetermined significance, immu

257 Preexisting plasma cell disorders, monoclonal gammopathy of undetermined significance, or s

258 er than in plasma cells from healthy donors, monoclonal gammopathy of undetermined significance, smol

259 evidence of paraproteinemia in a setting of monoclonal gammopathy of undetermined significance, smol

260 tive solution to delineate the complexity of monoclonal gammopathy of undetermined significance, smou

261 increased in both multiple myeloma (MM) and monoclonal gammopathy of undetermined significance, sugg

262 ong 5652 patients with IgG/IgA (but not IgM) monoclonal gammopathy of undetermined significance, supp

263 re akin to MM, whereas nonprogressor SMM has monoclonal gammopathy of undetermined significance-like

264 neuropathy, myeloproliferative disorder, and monoclonal gammopathy of undetermined significance.

265 ge-progressive premalignant condition termed monoclonal gammopathy of undetermined significance.

266 e marrow myeloma cells, even in asymptomatic monoclonal gammopathy of undetermined significance.

267 apheresis have shown limited efficacy in IgM monoclonal gammopathy of undetermined significance.

268 induced increase in MM cell proliferation in monoclonal gammopathy of undetermined significance/smold

269 higher levels of BM and circulating TPO than monoclonal gammopathy of undetermined significance/smold

270 Monoclonal gammopathy of unknown significance (MGUS) and

271 0%) methylation of SOCS1 and SYK; (5) MM and monoclonal gammopathy of unknown significance (MGUS) had

272 ra from patients with MM, chronic leukemias, monoclonal gammopathy of unknown significance (MGUS), PB

273 dults have the precursor malignant condition monoclonal gammopathy of unknown significance (MGUS).

274 ith multiple myeloma (MM) and its precursor, monoclonal gammopathy of unknown significance (MGUS).

275 Although the high prevalence of a monoclonal gammopathy of unknown significance in SCLS su

276 but not in the limited plasma cell disorder monoclonal gammopathy of unknown significance or in nonm

277 onsecutive patients with multiple myeloma or monoclonal gammopathy of unknown significance sequential

278 tomatic MM, 5 with smoldering MM, and 4 with monoclonal gammopathy of unknown significance) and 20 in

279 monoclonal T-cell populations, analogous to monoclonal gammopathy of unknown significance.

280 g revealed that the patient had unrecognized monoclonal gammopathy of unknown significance.

281 in patients with indolent smoldering MM and monoclonal gammopathy of unknown significance.

282 iple myeloma, marginal-zone lymphoma, or IgM monoclonal gammopathy of unknown significance.

283 hat proceeds through a premalignant state of monoclonal gammopathy of unknown significance; however,

284 e cohorts were at high risk for developing a monoclonal gammopathy on the basis of Black race or a fa

285 The constellation of lambda-restricted monoclonal gammopathy, plasma cell rimming around lympho

286 Paraproteinemia relates to monoclonal gammopathy-producing pathologic antibodies wi

287 eatures an unexpected low rate of detectable monoclonal gammopathy, questioning the reality of an und

288 e GN, alloimmune GN, autoinflammatory GN and monoclonal gammopathy-related GN.

289 s introduced by the International Kidney and Monoclonal Gammopathy Research Group (IKMG) in 2012.

290 thology Society and International Kidney and Monoclonal Gammopathy Research Group jointly tasked a wo

291 gkin lymphoma (RR, 2.35; 95% CI, 1.96-2.82), monoclonal gammopathy (RR, 1.90; 95% CI, 1.55-2.32), mye

292 athy (PPK) is a rare ocular manifestation of monoclonal gammopathies such as monoclonal gammopathy of

293 AL) and multiple myeloma (MM) are 2 distinct monoclonal gammopathies that involve the same cellular c

294 ficance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development o

295 IgG deposits, a form of renal involvement by monoclonal gammopathy that mimics immune-complex glomeru

296 Multiple myeloma is the most frequent monoclonal gammopathy to involve the kidney; however, a

297 ith end-stage renal disease and known benign monoclonal gammopathy underwent kidney transplantation a

298 Monoclonal gammopathy was of IgG type in 47 (94%) patien

299 All monoclonal gammopathies were associated with an increase

300 rdless of age, is frequently associated with monoclonal gammopathies, which often recognize various m

301 Our study suggests the association of monoclonal gammopathies with a variety of clinical pheno